Trial Profile
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Flotetuzumab (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus First in man; Therapeutic Use
- Acronyms VOYAGE
- Sponsors MacroGenics
- 15 Sep 2022 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 This trial has been completed in Netherlands (Date of the global end of the trial : 05-Jul-2022), according to European Clinical Trials Database record.
- 28 Aug 2022 This trial has been completed in Germany, according to European Clinical Trials Database record.